Biosimilars, a rapidly evolving field in biopharmaceutics, represent a groundbreaking category of therapeutic agents. These biological products, akin to existing biologics, are designed to demonstrate comparable efficacy, safety, and quality. Unlike generic drugs, biosimilars are complex and intricately manufactured, often involving living organisms.
The development of biosimilars is a result of advancements in biotechnology, allowing for the replication of intricate structures found in biopharmaceuticals. These products not only expand patient access to life-changing treatments but also contribute to healthcare affordability.
Biopharmaceutics focuses on understanding the complex interplay between biological systems and pharmaceutical formulations. Biosimilars, being part of this realm, undergo rigorous testing to ensure they meet stringent regulatory standards. As the industry continues to grow, the promise of biosimilars lies in their potential to enhance treatment options, promote competition, and foster innovation in the biopharmaceutical landscape.
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation